All In Biotech

Drug Trial Radar · NCT07038369

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

134

Planned (sponsor's estimate)

Start

Jul 29, 2025

Primary completion

Aug 31, 2028

Study completion Jan 31, 2029

Sponsor

Lead sponsor
Atavistik Bio, IncIndustry
Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with or without fulvestrant.

Conditions

  • Advanced Solid Tumors
  • Breast Cancer
  • Breast Carcinoma
  • Breast Neoplasms
  • ER Positive Breast Cancer
  • Cervical Cancers
  • Cervical Neoplasms
  • Cervical Carcinoma
  • Triple Negative Breast Cancer
  • Gynecologic Cancers
  • Gynecologic Neoplasm
  • Endometrial Cancer
  • Endometrial Neoplasm
  • Endometrial Carcinoma (EC)
  • Fallopian Cancer
  • Ovarian Carcinoma
  • Ovarian Cancer
  • Ovarian Neoplasms
  • Prostate Cancers
  • Prostate Carcinoma
  • Solid Tumors
  • Neoplasms
  • Neoplasms by Site
  • Breast Diseases
  • Uterine Neoplasms
  • Genital Neoplasms, Female
  • Urogenital Neoplasms

Interventions

  • ATV-1601Drug

    Drug: ATV-1601 • Oral ATV-1601

  • ATV-1601 + FulvestrantCombination product

    Drug: ATV-1601 * Oral ATV-1601 Drug: Fulvestrant * Intramuscular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Expansion: Maximum and minimum plasma concentrationTime frame: Approximately 48 months.
  2. Expansion: Time to C MaxTime frame: Approximately 48 months
  3. Expansion: Area under the concentration-time curveTime frame: Approximately 48 months
  4. Expansion: AUC at end of dosing intervalTime frame: Approximately 48 months
  5. Expansion: AUC extrapolated to infinityTime frame: Approximately 48 months
  6. Expansion: Half-lifeTime frame: Approximately 48 months
  7. Expansion: Trough ConcentrationsTime frame: Approximately 48 months
  8. Escalation & Expansion: Safety and Tolerability of monotherapy.Time frame: Approximately 48 months.
  9. Escalation: Maximum tolerated dose and/or recommended phase 2 dose of ATV-1601 in monotherapy.Time frame: Approximately 48 months.
  10. Escalation: Maximum tolerated dose and/or recommended phase 2 dose of ATV-1601 combination with fulvestrant.Time frame: Approximately 48 months.

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Florida Cancer Specialists & Research Institute - Lake Mary

    Lake Mary, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • MD Anderson Cancer Center

    Houston, Texas

  • Centre Leon Berard

    Lyon, France

  • National Cancer Centre Singapore

    Singapore, Singapore

  • START Madrid - CIOCC

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.